

Tanios S Bekaii-saab

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/10009411/publications.pdf](https://exaly.com/author-pdf/10009411/publications.pdf)

Version: 2024-02-01

210
papers

13,410
citations

31646

52
h-index

25840

106
g-index

370
all docs

370
docs citations

370
times ranked

23754
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved Risk-Stratification Scheme for Mismatch-Repair Proficient Stage II Colorectal Cancers Using the Digital Pathology Biomarker QuantCRC. <i>Clinical Cancer Research</i> , 2024, 30, 1811-1821.	7.2	0
2	Efficacy and Safety of Adagrasib plus Cetuximab in Patients with <i>KRAS</i> -G12C-Mutated Metastatic Colorectal Cancer. <i>Cancer Discovery</i> , 2024, 14, 982-993.	14.1	1
3	Clonal Hematopoiesis in Patients With Neuroendocrine Tumor Treated With Lutetium-177 and the Risk of Thrombocytopenia: A Prospective Study. <i>JCO Precision Oncology</i> , 2024, , .	3.1	0
4	Adjuvant <i>nab</i> -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2023, 41, 2007-2019.	5.4	44
5	Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial. <i>EClinicalMedicine</i> , 2023, 58, 101897.	7.1	9
6	Adagrasib in Advanced Solid Tumors Harboring a <i>KRAS</i> -G12C Mutation. <i>Journal of Clinical Oncology</i> , 2023, 41, 4097-4106.	5.4	64
7	Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes. <i>Oncologist</i> , 2023, 28, 885-893.	4.1	8
8	Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Clinic Experience. <i>JCO Precision Oncology</i> , 2023, , .	3.1	6
9	Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SCNTUC-019): A Phase II Basket Study. <i>Journal of Clinical Oncology</i> , 2023, 41, 5569-5578.	5.4	17
10	A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. <i>Investigational New Drugs</i> , 2022, 40, 134-141.	2.7	22
11	FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3797-3805.	2.4	5
12	Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. <i>JAMA Network Open</i> , 2022, 5, e2142046.	6.0	9
13	Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes. <i>JCO Precision Oncology</i> , 2022, 6, e2100156.	3.1	12
14	Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2022, 5, e2149040.	6.0	58
15	Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 437-441.	4.0	6
16	Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer. <i>JAMA Network Open</i> , 2022, 5, e224304.	6.0	45
17	Frontline therapy for advanced hepatocellular carcinoma: an update. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210861.	3.2	14
18	<i>BRAF</i> -Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape. <i>Journal of Clinical Oncology</i> , 2022, 40, 2706-2715.	5.4	36

#	ARTICLE	IF	CITATIONS
19	Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy. <i>JCO Precision Oncology</i> , 2022, , .	3.1	11
20	The Continued Struggle for Defining a Role for Radiotherapy in Pancreas Cancer. <i>JAMA Oncology</i> , 2022, 8, 1257.	7.3	6
21	Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482211153.	3.2	6
22	Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017. <i>Oncologist</i> , 2022, 27, 874-883.	4.1	32
23	Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 309-316.	4.0	36
24	Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1. <i>Pancreatology</i> , 2021, 21, 192-199.	1.8	8
25	Multi-Omics Data Analysis of Gene Expressions and Alterations, Cancer-Associated Fibroblast and Immune Infiltrations, Reveals the Onco-Immune Prognostic Relevance of STAT3/CDK2/4/6 in Human Malignancies. <i>Cancers</i> , 2021, 13, 954.	3.8	33
26	Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer. <i>Oncologist</i> , 2021, 26, 668-675.	4.1	25
27	Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. <i>Oncologist</i> , 2021, 26, 610-618.	4.1	5
28	ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 3641-3648.	7.2	37
29	Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?. <i>Seminars in Liver Disease</i> , 2021, 41, 136-141.	3.7	10
30	A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN G14-186. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3337-3348.	4.4	16
31	Comparison of Therapy in Advanced Hepatocellular Carcinoma Based on Clear Definition and Accurate Subgroup Dataâ€”Reply. <i>JAMA Oncology</i> , 2021, 7, 941.	7.3	0
32	First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. <i>European Journal of Cancer</i> , 2021, 151, 14-24.	2.9	25
33	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. <i>JAMA Oncology</i> , 2021, 7, 1167.	7.3	160
34	Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer and Exposureâ€”Safety Analyses in Patients With Metastatic Pancreatic Cancer. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, , .	2.5	6
35	Optimizing Chemotherapy Choice in the Treatment of Advanced Pancreatic Cancerâ€”It Is Complicated. <i>JAMA Network Open</i> , 2021, 4, e2134458.	6.0	5
36	Editorial comment on: Systemic treatment of hepatocellular carcinoma: An EASL position paper. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 11, 0-0.	1.2	0

#	ARTICLE	IF	CITATIONS
37	The Role of Maintenance Strategies in Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, e194489.	7.3	75
38	Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 101-109.	1.8	18
39	Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2020, 6, e204930.	7.3	144
40	Practical considerations in the use of regorafenib in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095686.	3.4	19
41	Suppressive myeloid cells are expanded by biliary tract cancer-derived cytokines in vitro and associate with aggressive disease. <i>British Journal of Cancer</i> , 2020, 123, 1377-1386.	6.5	4
42	Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model. <i>Oncolmmunology</i> , 2020, 9, 1818437.	4.7	22
43	Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. <i>Pancreatology</i> , 2020, 20, 1115-1122.	1.8	12
44	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , 2020, 395, 1907-1918.	12.1	1,443
45	Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors. <i>Oncologist</i> , 2020, 25, e1246-e1248.	4.1	3
46	Biliary tract cancer and genomic alterations in homologous recombinant deficiency: exploiting synthetic lethality with PARP inhibitors. <i>Chinese Clinical Oncology</i> , 2020, 9, 6-6.	1.3	18
47	Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. <i>Pancreas</i> , 2020, 49, 193-200.	1.1	31
48	Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor. <i>EMBO Molecular Medicine</i> , 2020, 12, e9910.	6.8	24
49	A Rare <i>EGFR</i> – <i>SEPT14</i> Fusion in a Patient with Colorectal Adenocarcinoma Responding to Erlotinib. <i>Oncologist</i> , 2020, 25, 203-207.	4.1	18
50	The Role of Maintenance Therapy in Metastatic Colorectal Cancer—Reply. <i>JAMA Oncology</i> , 2020, 6, 937.	7.3	1
51	Improvements in Clinical Outcomes for <i>BRAFV600E</i> -Mutant Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4435-4441.	7.2	17
52	Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3117-3125.	7.2	14
53	Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2020, 132, 112-121.	2.9	23
54	Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. <i>Journal of Hepatology</i> , 2020, 73, 1109-1117.	3.9	28

#	ARTICLE	IF	CITATIONS
55	Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. <i>Scientific Reports</i> , 2020, 10, 22087.	3.4	24
56	Systemic Treatment for Metastatic or Recurrent Disease. , 2020, , 275-287.		0
57	Precision Medicine in Metastatic Colorectal Cancerâ€”Finding and Hitting the Right Targets. <i>Oncology & Hematology Review</i> , 2020, 16, 36.	0.2	0
58	Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer. <i>Cancers</i> , 2019, 11, 1068.	3.8	21
59	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2019, 111, 782-794.	6.3	236
60	Therapeutic Targeting Strategies of Cancer Stem Cells in Gastrointestinal Malignancies. <i>Biomedicines</i> , 2019, 7, 17.	3.3	30
61	Watch and Wait in Rectal Cancer: Whoâ€™s In and Whoâ€™s Out?. <i>Journal of Oncology Practice</i> , 2019, 15, 133-134.	3.0	2
62	Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2019, 37, 1015-1027.	5.4	325
63	Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 3495-3507.	7.2	46
64	Canstem111P Trial: A Phase Iii Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine. <i>Future Oncology</i> , 2019, 15, 1295-1302.	2.4	40
65	Development and Validation of a Nomogram for Early Detection of Malignant Gallbladder Lesions. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00098.	2.5	18
66	A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 1174-1179.	4.1	16
67	Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	3.1	45
68	Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. <i>Clinical Colorectal Cancer</i> , 2019, 18, e117-e129.	2.4	57
69	Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 2403-2413.	7.2	43
70	Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. <i>Pancreatology</i> , 2019, 19, 80-87.	1.8	31
71	AJCC 8th edition staging system for pathologically versus clinically staged intrahepatic cholangiocarcinoma (iCCA): ready for prime time?. <i>Chinese Clinical Oncology</i> , 2019, 8, S19-S19.	1.3	1
72	A Clinical Trial Protocol Paper Discussing the Brighter Study. <i>Future Oncology</i> , 2018, 14, 901-906.	2.4	18

#	ARTICLE	IF	CITATIONS
73	Clinical Trials and Progress in Metastatic Colon Cancer. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 349-365.	1.5	65
74	Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway. <i>Oncogene</i> , 2018, 37, 3440-3455.	5.9	37
75	Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 140-146.	1.3	5
76	IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. <i>Gut</i> , 2018, 67, 320-332.	13.5	402
77	Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer. <i>Small GTPases</i> , 2018, 9, 452-456.	1.8	11
78	A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2018, 23, 25-34.	4.1	63
79	Trends in intensity modulated radiation therapy use for locally advanced rectal cancer at National Comprehensive Cancer Network centers. <i>Advances in Radiation Oncology</i> , 2018, 3, 34-41.	1.2	15
80	Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer. <i>International Journal of Cancer</i> , 2018, 142, 1671-1675.	5.4	8
81	Cholangiocarcinoma With <i>FGFR</i> Genetic Aberrations: A Unique Clinical Phenotype. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	3.1	108
82	Phase II Study of BGJ398 in Patients With <i>FGFR</i> -Altered Advanced Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 276-282.	5.4	554
83	A SEER-based multi-ethnic picture of advanced intrahepatic cholangiocarcinoma in the United States pre- and post-the advent of gemcitabine/cisplatin. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 1063-1073.	1.4	9
84	Antiangiogenic Therapy in Colorectal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 165-170.	2.0	84
85	Clinical update on K-Ras targeted therapy in gastrointestinal cancers. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 78-91.	4.5	19
86	Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma. <i>Cancers</i> , 2018, 10, 193.	3.8	16
87	The Efficacy of Adjuvant Chemotherapy in Patients With Stage II/III Resected Rectal Cancer Treated With Neoadjuvant Chemoradiation Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 531-534.	1.3	12
88	Perineural Invasion Predicts for Distant Metastasis in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation and Surgery. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 561-568.	1.3	23
89	Incidence and Survival of Appendiceal Mucinous Neoplasms. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 569-573.	1.3	49
90	Identifying and targeting cancer stem cells in the treatment of gastric cancer. <i>Cancer</i> , 2017, 123, 1303-1312.	4.1	93

#	ARTICLE	IF	CITATIONS
91	Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2017, 18, 446-453.	10.7	335
92	Signaling pathways as therapeutic targets in biliary tract cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 485-498.	3.4	6
93	Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment. <i>Cancer Research</i> , 2017, 77, 2647-2660.	0.9	119
94	Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2. <i>Nature Communications</i> , 2017, 8, 14755.	13.0	99
95	Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. <i>Cancer Treatment Reviews</i> , 2017, 60, 109-119.	8.0	45
96	Predictors of Pancreatic Cancerâ€™Associated Weight Loss and Nutritional Interventions. <i>Pancreas</i> , 2017, 46, 1152-1157.	1.1	62
97	Secondâ€™line treatment in patients with pancreatic ductal adenocarcinoma: A metaâ€™analysis. <i>Cancer</i> , 2017, 123, 4680-4686.	4.1	30
98	Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials. <i>BMC Cancer</i> , 2017, 17, 262.	2.6	16
99	Appendiceal Mucinous Neoplasms: Diagnosis and Management. <i>Oncologist</i> , 2017, 22, 1107-1116.	4.1	145
100	Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 344-356.	3.7	31
101	Gemcitabine-Associated Thrombotic Microangiopathy: Response to Complement Inhibition and Reinitiation of Gemcitabine. <i>Clinical Colorectal Cancer</i> , 2017, 16, e119-e122.	2.4	14
102	IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells. <i>Clinical Cancer Research</i> , 2017, 23, 489-502.	7.2	50
103	A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 75-82.	3.4	47
104	Autophagy Induction Results in Enhanced Anoikis Resistance in Models of Peritoneal Disease. <i>Molecular Cancer Research</i> , 2017, 15, 26-34.	3.5	33
105	The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies. <i>Biomedicines</i> , 2017, 5, 10.	3.3	11
106	Competitive Funding Strategies for the Conquer Cancer Foundation of ASCO. <i>Journal of Oncology Practice</i> , 2017, 13, e62-e67.	3.0	1
107	Response to Drs Von Hoff and Renschler. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 445-446.	3.4	0
108	Therapeutic options for intrahepatic cholangiocarcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2017, 6, 91-100.	1.2	13

#	ARTICLE	IF	CITATIONS
109	Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 293-301.	1.4	50
110	MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5931-5941.	2.1	6
111	Taking aim at the genomic diversity of gastrointestinal cancers: a changing landscape. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 673-674.	1.4	0
112	Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 2016, Volume 6, 21-30.	5.2	8
113	Appendiceal Mixed Adeno-Neuroendocrine Carcinoma: A Population-Based Study of the Surveillance, Epidemiology, and End Results Registry. <i>Frontiers in Oncology</i> , 2016, 6, 148.	2.9	34
114	Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 614-618.	1.3	14
115	Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42. <i>Neoplasia</i> , 2016, 18, 765-774.	5.3	16
116	Phase 1 Study of CEP-37250/KHK2804, a Tumor-specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors. <i>Targeted Oncology</i> , 2016, 11, 807-814.	3.7	4
117	Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer. <i>Medical Oncology</i> , 2016, 33, 48.	2.7	21
118	Mixed Adeno-neuroendocrine Carcinoma: An Aggressive Clinical Entity. <i>Annals of Surgical Oncology</i> , 2016, 23, 2281-2286.	1.9	51
119	Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. <i>Cancer</i> , 2016, 122, 3657-3666.	4.1	41
120	Outcomes of definitive chemoradiation in patients with esophageal cancer. <i>Ecological Management and Restoration</i> , 2016, 30, 1-7.	0.5	8
121	Biliary cancer: Utility of next-generation sequencing for clinical management. <i>Cancer</i> , 2016, 122, 3838-3847.	4.1	304
122	Adjuvant Chemotherapy for Rectal Cancer After Neoadjuvant Treatment: FOLFOX, 5-FU, or Observation. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 260-265.	0.5	0
123	Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer. <i>JAMA Surgery</i> , 2016, 151, e161137.	4.5	385
124	Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients: a single institute experience. <i>Medical Oncology</i> , 2016, 33, 4.	2.7	1
125	Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses. <i>Genetics in Medicine</i> , 2016, 18, 863-868.	2.4	33
126	Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv437.	6.3	21

#	ARTICLE	IF	CITATIONS
127	Adjuvant therapy for pancreas cancer in an era of value based cancer care. <i>Cancer Treatment Reviews</i> , 2016, 42, 10-17.	8.0	16
128	Successful Completion of Adjuvant Chemotherapy in a Patient With Colon Cancer Experiencing 5-Fluorouracil-Induced Cardiac Vasospasm. <i>Clinical Colorectal Cancer</i> , 2016, 15, e61-e63.	2.4	7
129	Application of next-generation sequencing in gastrointestinal and liver tumors. <i>Cancer Letters</i> , 2016, 374, 187-191.	7.3	14
130	Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2565-2574.	7.2	86
131	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2016, 387, 545-557.	12.1	925
132	A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 61-68.	7.2	107
133	Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors. <i>Oncotarget</i> , 2016, 7, 5306-5312.	1.9	7
134	Genomic diversity of colorectal cancer: Changing landscape and emerging targets. <i>World Journal of Gastroenterology</i> , 2016, 22, 5668.	3.4	14
135	Appendiceal Neuroendocrine, Goblet and Signet-Ring Cell Tumors: A Spectrum of Diseases with Different Patterns of Presentation and Outcome. <i>Cancer Research and Treatment</i> , 2016, 48, 596-604.	3.0	30
136	Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1005-1012.	2.4	3
137	Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer. <i>Scientific Reports</i> , 2015, 5, 12122.	3.4	61
138	Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). <i>Vaccines</i> , 2015, 3, 519-543.	4.5	17
139	Therapeutic Advances in Pancreatic Cancer: Miles to Go Before We Sleep. <i>Journal of the National Cancer Institute</i> , 2015, 107, dju439-dju439.	6.3	6
140	Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. <i>Oncologist</i> , 2015, 20, 1132-1139.	4.1	86
141	Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 149-159.	4.4	109
142	Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer. <i>Scientific Reports</i> , 2015, 5, 10867.	3.4	89
143	Second-line outcomes in metastatic colorectal cancer – raising the bar for the high jump rather than the doing the limbo. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 133-143.	1.4	2
144	Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 727-736.	4.4	49

#	ARTICLE	IF	CITATIONS
145	Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv274.	6.3	81
146	Maintenance Therapy for Colorectal Cancer: Which Regimen and Which Patients?. <i>Drugs</i> , 2015, 75, 1833-1842.	11.0	3
147	Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas. <i>Annals of Surgical Oncology</i> , 2015, 22, 1153-1159.	1.9	218
148	CA 19-9 as a Serum Biomarker in Cancer. <i>Biomarkers in Disease</i> , 2015, , 179-201.	0.0	2
149	Upfront molecular testing in patients with advanced gastro-esophageal cancer: Is it time yet?. <i>Oncotarget</i> , 2015, 6, 22206-22213.	1.9	7
150	Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer. <i>Oncotarget</i> , 2015, 6, 44509-44522.	1.9	16
151	Systemic Treatment for Metastatic or Recurrent Disease. , 2015, , 221-244.		0
152	Ampullary Cancer: An Overview. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , 112-115.	4.0	89
153	Outcomes in Patients with Obstructive Jaundice from Metastatic Colorectal Cancer and Implications for Management. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 2186-2191.	2.1	13
154	Incidence of Minimally Invasive Colorectal Cancer Surgery at National Comprehensive Cancer Network Centers. <i>Journal of the National Cancer Institute</i> , 2014, 107, dju362-dju362.	6.3	48
155	Prostate cancer incidence in males with Lynch syndrome. <i>Genetics in Medicine</i> , 2014, 16, 553-557.	2.4	91
156	Processes of Care in the Multidisciplinary Treatment of Gastric Cancer. <i>JAMA Surgery</i> , 2014, 149, 18.	4.5	36
157	Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. <i>Cancer</i> , 2014, 120, 1780-1786.	4.1	24
158	CA 19-9 as a Serum Biomarker in Cancer. , 2014, , 1-19.		0
159	Should Combination Chemotherapy Serve as the Backbone in Clinical Trials of Advanced Pancreatic Cancer?. <i>Pancreas</i> , 2014, 43, 343-349.	1.1	8
160	Optimal Management of Gastric Cancer. <i>Annals of Surgery</i> , 2014, 259, 102-108.	4.4	48
161	The Addition of Radiation to Chemotherapy does not Improve Outcome When Compared to Chemotherapy in the Treatment of Resected Pancreas Cancer: The Results of a Single-Institution Experience. <i>Annals of Surgical Oncology</i> , 2014, 21, 862-867.	1.9	5
162	Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. <i>Investigational New Drugs</i> , 2014, 32, 113-122.	2.7	42

#	ARTICLE	IF	CITATIONS
163	Seeing the forest through the trees: A systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 91, 9-34.	4.5	27
164	Pain, depression, and fatigue: Loneliness as a longitudinal risk factor.. <i>Health Psychology</i> , 2014, 33, 948-957.	1.6	252
165	Carbohydrate antigen 19â€9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabineâ€containing chemotherapy. <i>Cancer</i> , 2013, 119, 285-292.	4.1	105
166	A multiâ€institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. <i>Cancer</i> , 2013, 119, 2692-2700.	4.1	168
167	Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1499-1506.	2.4	51
168	Peptide Vaccines and Peptidomimetics of EGFR (HER-1) Ligand Binding Domain Inhibit Cancer Cell Growth In Vitro and In Vivo. <i>Journal of Immunology</i> , 2013, 191, 217-227.	0.8	40
169	Defining Surgical Quality in Gastric Cancer: A RAND/UCLA Appropriateness Study. <i>Journal of the American College of Surgeons</i> , 2013, 217, 347-357e1.	0.5	42
170	A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 685-695.	2.7	26
171	What provider volumes and characteristics are appropriate for gastric cancer resection? Results ofÂanÂinternational RAND/UCLA expertÂpanel. <i>Surgery</i> , 2013, 154, 1100-1109.	2.0	14
172	A phase II study of modulated-capecitabine and docetaxel in chemo-naïve patients with advanced non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2013, 79, 27-32.	2.0	4
173	A RAND/UCLA Appropriateness Study of the Management of Familial Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 533-541.	1.9	12
174	<i>RAS</i> mutations: impact on treatment outcome. <i>Colorectal Cancer</i> , 2013, 2, 525-534.	0.9	0
175	FOLFIRINOX in Locally Advanced Pancreas Adenocarcinoma: Back to the Future?. <i>Oncologist</i> , 2013, 18, 487-489.	4.1	4
176	Pancreatic Cancer-Associated Stellate Cells Promote Differentiation of Myeloid-Derived Suppressor Cells in a STAT3-Dependent Manner. <i>Cancer Research</i> , 2013, 73, 3007-3018.	0.9	352
177	Recurrent Life-Threatening Deep Tissue Hematomas After Switching to Generic Enoxaparin: A Report and Perspective on the Approval Process for Biological Compounds. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2012, 18, 104-106.	1.7	2
178	A Dose Escalation and Pharmacodynamic Study of Triapine and Radiation in Patients With Locally Advanced Pancreas Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, e475-e481.	0.8	18
179	Yttrium-90 Radioembolization as Salvage Therapy for Colorectal Cancer With Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2012, 11, 195-199.	2.4	26
180	Adjuvant Therapy Following Curative Resection of Metastases. <i>Current Colorectal Cancer Reports</i> , 2012, 8, 217-224.	0.5	0

#	ARTICLE	IF	CITATIONS
181	Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer. <i>Medical Oncology</i> , 2012, 29, 3101-3107.	2.7	24
182	Photodynamic Therapy (PDT) May Provide Effective Palliation in the Treatment of Primary Tracheal Carcinoma: A Small Case Series. <i>Photomedicine and Laser Surgery</i> , 2012, 30, 668-671.	2.1	3
183	O-0002 A Phase 2 Adjuvant Trial of GI-4000 Plus Gemcitabine vs. Gemcitabine Alone in Ras+ Patients with Resected Pancreas Cancer: R1 Subgroup Analysis. <i>Annals of Oncology</i> , 2012, 23, iv5.	1.3	5
184	Fractionated radioimmunotherapy with ⁹⁰ Y-εlivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer. <i>Cancer</i> , 2012, 118, 5497-5506.	4.1	81
185	Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma. <i>Cancer</i> , 2012, 118, 6243-6252.	4.1	20
186	A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2012, 30, 629-638.	2.7	25
187	STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH+/CD133+ stem cell-like human colon cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2011, 416, 246-251.	2.2	114
188	Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer. <i>Investigational New Drugs</i> , 2011, 29, 347-351.	2.7	23
189	A phase I study of topotecan and gemcitabine in advanced solid tumors. <i>Investigational New Drugs</i> , 2011, 29, 1390-1394.	2.7	0
190	Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4+ T cells from patients with GI malignancy. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1269-1279.	4.4	135
191	A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 511-517.	2.4	8
192	Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers. <i>Journal of Clinical Oncology</i> , 2011, 29, 2357-2363.	5.4	277
193	Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2010, 5, 713-718.	1.2	14
194	Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 319-324.	2.4	5
195	A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 863-869.	2.4	0
196	A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 151-158.	2.4	12
197	Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 1019-1029.	2.4	19
198	A Cancer and Leukemia Group B Phase II Study of Sunitinib Malate in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma (CALGB 80603). <i>Oncologist</i> , 2010, 15, 1310-1319.	4.1	61

#	ARTICLE	IF	CITATIONS
199	A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas. <i>Clinical Cancer Research</i> , 2009, 15, 5895-5901.	7.2	103
200	KRAS Testing in Metastatic Colorectal Cancer: Implications on the Use of Biologic Agents. <i>Clinical Colorectal Cancer</i> , 2009, 8, 135-140.	2.4	4
201	Curcumin analogues exhibit enhanced growth suppressive activity in human pancreatic cancer cells. <i>Anti-Cancer Drugs</i> , 2009, 20, 444-449.	1.4	58
202	Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report. <i>Journal of Hematology and Oncology</i> , 2008, 1, 18.	17.5	50
203	A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. <i>BMC Cancer</i> , 2006, 6, 278.	2.6	46
204	Incorporation of photodynamic therapy as an induction modality in non-small cell lung cancer. <i>Lasers in Surgery and Medicine</i> , 2006, 38, 881-889.	2.1	36
205	UDP-Glucuronosyltransferase (UGT) 2B15 Pharmacogenetics: UGT2B15 D85Y Genotype and Gender Are Major Determinants of Oxazepam Glucuronidation by Human Liver. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 310, 656-665.	2.4	105
206	Late Relapse of Ovarian Dysgerminoma: Case Report and Literature Review. <i>Gynecologic Oncology</i> , 1999, 72, 111-112.	1.4	11
207	ZEBRA: An IRCI/ACCRU (RUO21502I) Multicenter Phase II Study of Pembrolizumab in Patients With Advanced Small Bowel Adenocarcinoma (SBA). <i>SSRN Electronic Journal</i> , 0, , .	0.3	0
208	Phase IIIb study of the bevacizumab biosimilar candidate BI 695502 plus mFOLFOX6 in metastatic colorectal cancer. <i>Colorectal Cancer</i> , 0, , .	0.9	0
209	PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF- κ B Signaling in Patients with Pancreatic Cancer. <i>Clinical Cancer Research</i> , 0, , OF1-OF12.	7.2	1
210	Guide to Understanding and Supporting International Medical Graduates in Hematology/Oncology by the ASCO International Medical Graduates Community of Practice. <i>JCO Oncology Practice</i> , 0, , .	2.7	0